PI3K inhibition in inflammation: Toward tailored therapies for specific diseases
- PMID: 20162662
- DOI: 10.1002/bies.200900150
PI3K inhibition in inflammation: Toward tailored therapies for specific diseases
Abstract
In the past decade, the availability of genetically modified animals has enabled the discovery of interesting roles for phosphatidylinositol 3-kinase-gamma (PI3Kgamma) and -delta (PI3Kdelta) in different cell types orchestrating innate and adaptive immune responses. Therefore, these PI3K isoforms appear to be attractive drug targets for the treatment of diseases caused by unrestrained immune reactions. Currently, pharmacological targeting of PI3Kgamma and/or PI3Kdelta represents one of the most promising challenges for companies interested in the development of novel safe treatments for inflammatory diseases. In this review we provide a general outline of PI3Kgamma- and PI3Kdelta-specific functions in distinct subsets of inflammatory cells. We also discuss the therapeutic impact of novel compounds targeting PI3Kgamma, PI3Kdelta or both, in mouse models of autoimmune disorders (systemic lupus erythematosus (SLE) and rheumatoid arthritis), respiratory diseases (allergic asthma and chronic obstructive pulmonary disease) and cardiovascular dysfunctions (atherosclerosis and myocardial infarction).
Similar articles
-
Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.Biochem Soc Trans. 2018 Apr 17;46(2):361-369. doi: 10.1042/BST20170467. Epub 2018 Mar 9. Biochem Soc Trans. 2018. PMID: 29523773 Review.
-
PI3K signalling in inflammation.Biochim Biophys Acta. 2015 Jun;1851(6):882-97. doi: 10.1016/j.bbalip.2014.12.006. Epub 2014 Dec 13. Biochim Biophys Acta. 2015. PMID: 25514767 Review.
-
Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.J Allergy Clin Immunol. 2013 Oct;132(4):959-68. doi: 10.1016/j.jaci.2013.03.008. Epub 2013 May 14. J Allergy Clin Immunol. 2013. PMID: 23683463
-
Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function.Cell Signal. 2011 Apr;23(4):603-8. doi: 10.1016/j.cellsig.2010.10.002. Epub 2010 Oct 16. Cell Signal. 2011. PMID: 20940048 Review.
-
Targeting phosphoinositide 3-kinase: moving towards therapy.Biochim Biophys Acta. 2008 Jan;1784(1):159-85. doi: 10.1016/j.bbapap.2007.10.003. Epub 2007 Oct 12. Biochim Biophys Acta. 2008. PMID: 17997386 Review.
Cited by
-
PI3K-γ inhibitors in the therapeutic intervention of diseases caused by obligate intracellular pathogens.Commun Integr Biol. 2013 Mar 1;6(2):e23360. doi: 10.4161/cib.23360. Commun Integr Biol. 2013. PMID: 23749323 Free PMC article.
-
The Inhibition of Phosphoinositide-3 Kinases Induce Resolution of Inflammation in a Gout Model.Front Pharmacol. 2019 Jan 7;9:1505. doi: 10.3389/fphar.2018.01505. eCollection 2018. Front Pharmacol. 2019. PMID: 30666201 Free PMC article.
-
p110γ/δ Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation.PLoS One. 2016 Jul 21;11(7):e0159310. doi: 10.1371/journal.pone.0159310. eCollection 2016. PLoS One. 2016. PMID: 27442134 Free PMC article.
-
A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.Nat Chem Biol. 2012 Apr 29;8(6):576-82. doi: 10.1038/nchembio.957. Nat Chem Biol. 2012. PMID: 22544264
-
Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy.Cancer Med. 2016 Jan;5(1):24-32. doi: 10.1002/cam4.564. Epub 2015 Dec 8. Cancer Med. 2016. PMID: 26645682 Free PMC article.
References
-
- Dhand R, Hiles I, Panayotou G, et al. 1994. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. Embo J 13: 522-33.
-
- Lehmann K, Muller JP, Schlott B, et al. 2009. PI3Kgamma controls oxidative bursts in neutrophils via interactions with PKCalpha and p47phox. Biochem J 419: 603-10.
-
- Yu J, Zhang Y, McIlroy J, et al. 1998. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-87.
-
- Geering B, Cutillas PR, Nock G, et al. 2007. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 104: 7809-14.
-
- Ueki K, Fruman DA, Yballe CM, et al. 2003. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278: 48453-66.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous